|
|
News Breaks
|
November 27, 2009
|
| 13:32 EDT |  | THRX |
| theflyonthewall.com: | Theravance recieves complete response letter on the Telavancin NDA | | Theravance announced that it received a Complete Response letter from the U.S. FDA related to the telavancin New Drug Application for the treatment of nosocomial pneumonia. Telavancin is a bactericidal, once-daily injectable investigational antibiotic for the treatment of NP caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus. VIBATIV is approved in theUnited States and in Canada for the treatment of adult patients with complicated skin and skinstructure infections caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group and Enterococcus faecalis. :theflyonthewall.com |
|
|
News For THRX From The Last 14 Days Check below for free stories on THRX the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 16:22 EDT |  | THRX |
|
|
January 31, 2012
|
| 11:21 EDT |  | THRX |
| | 10:28 EDT |  | THRX |
| | 06:11 EDT | | THRX |
| theflyonthewall.com: | Theravance initiated with an Underweight at Morgan Stanley | | Target $12. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information